The Agos­ti­ni’s Group said yes­ter­day that its prof­it at­trib­ut­able to share­hold­ers, ex­clud­ing the one-off, non-cash net gain on ac­qui­si­tions in 2023, de­creased by 3 per cent from $182 mil­lion to $177 mil­lion, for nine-month pe­ri­od end­ed June 30, 2024.

In the com­pa­ny’s fi­nan­cial state­ment for the pe­ri­od Oc­to­ber 1, 2023 to June 30, 2024 the group re­port­ed that sales in­creased by eight per cent over the pri­or pe­ri­od to $3.8 bil­lion, while for the three months end­ed 30 June, 2024, rev­enue and prof­it af­ter tax (ex­clud­ing the ad­just­ment for the net gain) in­creased by nine per cent and four per cent, re­spec­tive­ly, ver­sus the same quar­ter in the pri­or year.

The group said it is mak­ing sig­nif­i­cant progress in the struc­tur­ing of its phar­ma­ceu­ti­cal and health­care and con­sumer prod­ucts seg­ments, as it out­lined plans to in­te­grate and stream­line re­gion­al op­er­a­tions in each seg­ment to take ad­van­tage of strengths in each mar­ket and po­si­tion the Group for fu­ture growth.

The com­pa­ny once again stat­ed that at the end of June the group com­plet­ed the ac­qui­si­tion of the Aven­ta group in Cu­ra­cao and Aru­ba, a lead­ing phar­ma­ceu­ti­cal dis­tri­b­u­tion com­pa­ny in the Dutch Caribbean.

Agos­ti­ni’s chair­man Chris­t­ian Mout­tet said “This ac­qui­si­tion is in align­ment with our re­gion­al growth strat­e­gy and adds key mar­kets and ex­per­tise to our phar­ma­ceu­ti­cal and health­care fran­chise.”

Mout­tet added, “In ad­di­tion to our re­cent ac­qui­si­tions, the Group is in­vest­ing sig­nif­i­cant­ly in hu­man re­source de­vel­op­ment, in­no­va­tion and in­for­ma­tion tech­nol­o­gy trans­for­ma­tion. These in­vest­ments will build over­all ca­pac­i­ty, con­tin­ue to fos­ter an en­vi­ron­ment for in­di­vid­ual de­vel­op­ment and ad­vance­ment, and pro­vide a plat­form for long term sus­tain­able growth.”